Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related
peptide, has shown migraine preventive effects starting the day following infusion and …

Importance Approximately 90% of people in the US experience headache during their
lifetime. Migraine is the second leading cause of years lived with disability worldwide …

Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Background Several novel treatments targeting the calcitonin gene-related peptide pathway
have been developed for migraine. We evaluated the efficacy of these medications …

Background Several drugs are available for the preventive treatment of both episodic and
chronic migraine. The choice of which therapy to initiate first, second, or third is not …

Migraine is a highly disabling neurovascular disorder characterized by a severe headache
(associated with nausea, photophobia and/or phonophobia), and trigeminovascular system …

Objective While there are several trials that support the efficacy of various drugs for migraine
prophylaxis against placebo, there is limited evidence addressing the comparative safety …